ÂÜÀòÂÒÂ×

Eddie’s background combines deep scientific and business experience in biotechnology. At MIT, Eddie’s doctoral studies focused on the development of non-viral gene therapies. After earning his PhD, he joined an early-stage ocular drug delivery company as a scientist on formulation and process scale-up for two clinical drug products, now FDA-approved. Eddie went on to pursue MBA internships at Roche/Genentech and in VC at NanoDimension, before serving as the Head of Corporate Development at Senti Bio, a Pear portfolio company that leverages synthetic biology for next-generation cell and gene therapies.

At Pear, Eddie leads the firm’s investments in companies specializing in innovative Life Sciences. He loves supporting visionary founders in their missions to transform human health and is passionate about the commercial and clinical translation of cutting-edge Life Sciences technologies.